Search hospitals > Nevada > Las Vegas

Hope Cancer Care of Nevada

Claim this profile
Las Vegas, Nevada 89103
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Adenocarcinoma
Conducts research for Non-Small Cell Lung Cancer
103 reported clinical trials
2 medical researchers
Photo of Hope Cancer Care of Nevada in Las VegasPhoto of Hope Cancer Care of Nevada in Las VegasPhoto of Hope Cancer Care of Nevada in Las Vegas

Summary

Hope Cancer Care of Nevada is a medical facility located in Las Vegas, Nevada. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Hope Cancer Care of Nevada is involved with conducting 103 clinical trials across 262 conditions. There are 2 research doctors associated with this hospital, such as John A. Ellerton and Alan K. Ikeda.

Area of expertise

1Cancer
Global Leader
Hope Cancer Care of Nevada has run 53 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage I
2Lung Cancer
Global Leader
Hope Cancer Care of Nevada has run 19 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Top PIs

Clinical Trials running at Hope Cancer Care of Nevada

Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Cancer
Bladder Carcinoma
Gastric Cancer
Renal Cell Carcinoma
Esophageal Cancer
Adenocarcinoma
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Support Program

for Breast Cancer

This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Image of trial facility.

Symptom Monitoring

for Young Women on Hormone Therapy

This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can cause side effects, and may cause some women to stop treatment early. Asking about symptoms more often may help women keep taking hormone therapy medicines.
Recruiting1 award N/A13 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Hope Cancer Care of Nevada?
Hope Cancer Care of Nevada is a medical facility located in Las Vegas, Nevada. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Hope Cancer Care of Nevada is involved with conducting 103 clinical trials across 262 conditions. There are 2 research doctors associated with this hospital, such as John A. Ellerton and Alan K. Ikeda.